The renewal was followed by a cGMP inspection conducted by Spanish health authorities at the manufacturing facility.
TiGenix CTO Wilfried Dalemans said the Madrid GMP facility manufactures high-quality, clinical grade allogeneic stem cell products.
"It is an important stepping stone before we can move to commercial manufacturing at our state-of-the-art, central GMP manufacturing site in Sittard-Geleen, the Netherlands," Dalemans added.